Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.

Artikel i vetenskaplig tidskrift
Författare Andreas Josefsson
Anna Linder
Despina Flondell Site
Giacomo Canesin
Anna Stiehm
Aseem Anand
Anders Bjartell
Jan-Erik Damber
Karin Welén
Publicerad i The Prostate
Volym 77
Nummer/häfte 8
Sidor 849–858
ISSN 1097-0045
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för urologi
Sahlgrenska Cancer Center
Sidor 849–858
Språk en
Länkar dx.doi.org/10.1002/pros.23325
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämneskategorier Cancer och onkologi, Urologi och njurmedicin, Urologi och andrologi

Sammanfattning

Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC).PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression.At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression-free survival, whereas PSA and alkaline phosphatase serum levels, Gleason score, or T-stage were not. EGFR-positive patients had significantly shorter time to progression (5 months) compared to EGFR-negative patients (11 months) (P < 0.05).In this explorative study, CTCs were detected in 98% of M1 patients and detection of EGFR in CTCs was strongly associated with poor outcome, which indicated that phenotypical analysis of CTC could be a promising prognostic marker of ADT-response in castration-naïve metastatic PC patients. Prostate 2017. © 2017 Wiley Periodicals, Inc.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?